KRAS and acute myeloid leukemia: SOM meta-clade 21 is the location of the FDA compound cytarabine (ara-C) and is consistent with the conclusion of Ahmad et al [24] that adult AML patients carrying defective KRAS benefit from higher ara-C doses more than wt KRAS patients.